

November 19, 2025

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001	The National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051
---	--

Scrip Code: 541540, 890202

Scrip Code: SOLARA, SOLARAPP1

Dear Sir/ Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled hereunder, with respect to the EIR (Establishment Inspection Report) received from US FDA for the inspection completed and classified as VAI (Voluntary Action Indicated).

“Solara is pleased to announce the successful closure of US FDA inspection of its Mangalore Facility with continued state of compliance on cGMP”

Thanking you,

Yours Faithfully,

For Solara Active Pharma Sciences Limited

Pooja Jaya Kumar
Company Secretary and Compliance Officer
Membership No: A57415

Solara is pleased to announce the successful closure of US FDA inspection of its Mangalore Facility with continued state of compliance on cGMP

Chennai, India – Nov 19, 2025: Solara Active Pharma Sciences Limited (Solara), a leading pure play Active Pharmaceutical Ingredient provider is pleased to announce that its multi-product manufacturing facility at Mangalore, Karnataka has successfully completed the inspection carried out by the US Food and Drug Administration (US FDA) between 25th to 29th Aug 2025. The Agency has issued an EIR (Establishment Inspection Report) on 18th Nov 2025 and determined that the inspection classification of the facility is “Voluntary Action Indicated (VAI)” and concluded this inspection as closed.

Solara continues to stay focused on maintaining the highest level of compliance across its manufacturing facilities.

Commenting on the Inspection Outcome, Sandeep Rao, MD & CEO said “We have successfully completed the FDA inspection at our Mangalore facility between 25th to 29th Aug 2025. At the end of the inspection, two Form FDA 483 inspectional observations were issued by the investigator. The observations were procedural in nature. We had submitted our formal response to FDA well within the timeline set by the Agency and the Agency has issued an EIR and concluded that the inspection is closed. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.”

The Mangalore multi-product API manufacturing facility is well equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, EDQM, HPRA, TGA, WHO, PMDA, and MFDS, Korea.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540;890202, NSE-SOLARA; SOLARAPP1) is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, Solara offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services. Its API facilities are approved by various international regulatory agencies including the USFDA, EDQM, MFDS, WHO, PMDA etc.

Investor / Analyst contact

Abhishek Singhal

✉ abhishek.singhal@solara.co.in

☎ +91 99877 66968

Statutory and corporate affairs

Pooja Jaya Kumar

Raghavan. V

✉ investors@solara.co.in

Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.